Evelo Biosciences is a clinical-stage company pioneering the development of monoclonal microbials, a new class of therapies designed to act on the gut-body network. Monoclonal microbial product candidates are orally-delivered pharmaceutical compositions of specific strains of naturally-occurring microbes and are intended to modulate systemic immune response by acting on the gut-body network through multiple naturally-evolved biological pathways. Evelo believes monoclonal microbials have the potential to be broadly applicable across many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications
January 4, 2019